Suppr
超能文献

EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.

作者信息

Moore Sara, Wheatley-Price Paul

机构信息

Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

出版信息

J Thorac Oncol. 2021 Nov;16(11):1788-1792. doi: 10.1016/j.jtho.2021.06.004.

DOI:10.1016/j.jtho.2021.06.004

PMID:34716002

Abstract

摘要

相似文献

EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.

J Thorac Oncol. 2021 Nov;16(11):1788-1792. doi: 10.1016/j.jtho.2021.06.004.

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.

J Thorac Oncol. 2021 Nov;16(11):1793-1797. doi: 10.1016/j.jtho.2021.08.015.

Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.

Pulmonology. 2019 Sep-Oct;25(5):306-309. doi: 10.1016/j.pulmoe.2019.04.005. Epub 2019 Jun 7.

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).

Cancer Commun (Lond). 2019 Nov 7;39(1):69. doi: 10.1186/s40880-019-0414-4.

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.

Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?

Lancet Respir Med. 2023 Oct;11(10):857-859. doi: 10.1016/S2213-2600(23)00216-3. Epub 2023 May 24.

Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.

Adv Ther. 2020 Feb;37(2):946-954. doi: 10.1007/s12325-020-01221-4. Epub 2020 Jan 18.

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.

Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(7):266-272. doi: 10.2183/pjab.96.020.

Third-generation EGFR-TKIs—a new hope for NSCLC.

Lancet Respir Med. 2014 Jul;2(7):520. doi: 10.1016/s2213-2600(14)70095-5.

New data highlighting the efficacy and safety outcomes of third-generation EGFR-TKI in NSCLC patients with rare EGFR mutations.

Thorac Cancer. 2020 Mar;11(3):495-497. doi: 10.1111/1759-7714.13334. Epub 2020 Jan 28.

引用本文的文献

Comparative analysis of first-generation epidermal growth factor receptor inhibitors combined with chemotherapy versus third-generation epidermal growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis.

Front Pharmacol. 2025 Aug 14;16:1586332. doi: 10.3389/fphar.2025.1586332. eCollection 2025.

EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI.

Cancer Cell Int. 2025 Feb 19;25(1):55. doi: 10.1186/s12935-025-03691-4.

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.

Cancer Commun (Lond). 2024 Oct;44(10):1189-1208. doi: 10.1002/cac2.12602. Epub 2024 Aug 19.

Computed Tomography-derived intratumoral and peritumoral radiomics in predicting EGFR mutation in lung adenocarcinoma.

Radiol Med. 2023 Dec;128(12):1483-1496. doi: 10.1007/s11547-023-01722-6. Epub 2023 Sep 25.

A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202.

Oncol Lett. 2023 Jun 20;26(2):334. doi: 10.3892/ol.2023.13920. eCollection 2023 Aug.

Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer.

Beilstein J Nanotechnol. 2023 Feb 22;14:240-261. doi: 10.3762/bjnano.14.23. eCollection 2023.

Structure-based classification of mutations in operable pre-invasive and invasive non-small cell lung cancer: a cross-sectional study.

J Thorac Dis. 2022 Sep;14(9):3508-3516. doi: 10.21037/jtd-22-1054.

Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC.

Emerg Med Int. 2022 Jun 10;2022:3112281. doi: 10.1155/2022/3112281. eCollection 2022.

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.

J Thorac Oncol. 2022 Jun;17(6):779-792. doi: 10.1016/j.jtho.2022.02.011. Epub 2022 Mar 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译